Shingles Vaccine for HIV-Infected Adults
SSS health researcher Dawn Bozzolo is among the authors of an article in Clinical Infectious Diseases about the safety and immunogenicity of live attenuated zoster vaccine (ZV) in HIV-infected adults—of interest because HIV-infected persons are at increased risk for herpes zoster (shingles). The article describes the results of a randomized, double-blind, placebo-controlled trial in HIV-infected adults virologically suppressed on antiretroviral therapy, and determined that two doses of ZV were generally safe and immunogenic. Other authors of the article include researchers from the University of California San Diego, Harvard School of Public Health, University of Pittsburgh, the National Institute of Allergy and Infectious Diseases, Rush University, University of Rochester, Weill Cornell Medical College, University of Pennsylvania Perelman School of Medicine, Merck & Co., and Emory University.
Read more about SSS research activities in our online publication SSS Update.